AstraZeneca’s U.S. Trial Remains on Hold Pending FDA Review (2)
By Riley Griffin
Sept. 16, 2020, 1:03 PM
AstraZeneca Plc’s Covid-19 vaccine study remains paused in the U.S. pending a regulatory review of an incident in which a U.K. participant became ill, federal officials said.
The British drugmaker and its partner, the University of Oxford, put research into the shot on hold last week after the volunteer suffered neurological symptoms. Trials resumed in the U.K. over the weekend, while researchers in South Africa also restarted tests, saying that an independent safety committee concluded that the event was unlikely to be related to the vaccination.
Temporary pauses in clinical trials aren’t unusual. However, the reported event has heightened...